Physician profile
Robert Grant
NPI 1508823659
$7,711.24
in general payments reported to CMS, 2019-2025
17 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $4,831 · 2022: $223 · 2023: $618 · 2024: $899 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,477 · Education: $55.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,477.36 |
| Education | $55.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $5,270.72 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $461.53 | 2022-2025 | Ofev, Jascayd, Stiolto Respimat |
| Insmed, INC. | $439.64 | 2022-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $432.21 | 2020-2025 | Airsupra, Breztri, Fasenra |
| Regeneron Healthcare Solutions, INC. | $244.65 | 2023-2025 | Dupixent |
| Amgen INC. | $152.98 | 2022-2025 | Tezspire |
| United Therapeutics Corporation | $149.18 | 2023-2025 | Tyvaso, Tyvaso |
| Mylan Specialty L.P. | $134.31 | 2023-2024 | Yupelri |
| Genzyme Corporation | $110.61 | 2022-2025 | |
| Inogen, INC. | $103.11 | 2024 | |
| Verona Pharma, INC. | $58.08 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $35.71 | 2024 | Inspire |
| Actelion Pharmaceuticals US, INC. | $27.83 | 2025 | Opsumit |
| Resmed Corp | $26.76 | 2023 | |
| Fisher & Paykel Healthcare INC | $26.44 | 2024 | Fisher & Paykel Healthcare |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $19.28 | 2025 | Zepbound |
| Grifols USA, LLC | $18.20 | 2023 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.